Welcome to our dedicated page for Centessa Pharmaceuticals plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Form 144 notice for Centessa Pharmaceuticals plc (CNTA) reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/10/2025 on NASDAQ with an aggregate market value of $550,000.00. The shares were acquired and paid for on 09/10/2025 by exercise of a stock option and payment in cash. The filing lists 134,073,436 shares outstanding. The filing also discloses a sale the prior day: 24,792 shares sold on 09/09/2025 for gross proceeds of $495,840.00 by Tia Bush. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1/trading-plan language.
Form 144 filed for Centessa Pharmaceuticals plc (CNTA) shows a proposed sale of 20,000 common shares through UBS Financial Services with an aggregate market value of $440,000.00, listed on Nasdaq. The shares were acquired on 09/10/2025 by exercise of stock options and payment was in cash. The filing notes the issuer has 134,073,436 shares outstanding, and the proposed sale is scheduled for 09/10/2025. The document also discloses sales by the same person totaling 44,000 shares in the past three months for gross proceeds of $761,267.20, with individual sale dates and proceeds listed. The filer affirms no undisclosed material adverse information.
Centessa Pharmaceuticals plc (CNTA) reported a Form 144 notice showing an insider sale tied to a same-day option exercise. The filer intends to sell 24,792 shares of common stock on 09/09/2025 through UBS Financial Services (11 Madison Ave., New York) on the NASDAQ, with an aggregate market value of $495,840.00. The filing lists total shares outstanding as 134,073,436. The acquisition details state the shares were acquired by exercise of a stock option on 09/09/2025 and paid for in cash. The form indicates there were no securities sold by the reporting person in the past three months.
Form 144 notice by an insider of Centessa Pharmaceuticals plc (CNTA) reporting a proposed sale of 7,000 common shares through UBS Financial Services with an aggregate market value of $140,000. The filing shows total shares outstanding of 134,073,436, and lists the insider's prior acquisitions: 2,000 founder shares acquired 01/02/2020 and 5,000 shares from an exercise of options on 09/09/2025 (paid in cash). The filing also discloses sales by the same person during the past three months: 15,000 shares on 06/24/2025 for $210,000 and 8,322 shares on 07/29/2025 for $126,750.72. The notice includes the required representation that the seller does not possess undisclosed material adverse information.
Form 144 notice for proposed sale of securities. The filing shows a proposed sale of 20,000 shares of common stock through UBS Financial Services on 09/09/2025 on Nasdaq with an aggregate market value of $400,102.00. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The filer also reported three prior sales during the past three months totaling 24,000 common shares with gross proceeds of $360,165.20 from sales on 06/24/2025, 07/15/2025, and 08/15/2025. The filing includes the seller's name and broker details.
Centessa Pharmaceuticals plc (CNTA) reporting person Hussain Iqbal J, General Counsel, executed option exercise and a sale on 08/15/2025. The filing shows the reporting person exercised a share option to acquire 6,000 ordinary shares at an exercise price of $5.84 per share and immediately sold 6,000 ordinary shares at $17.23 per share, leaving 105,386 shares owned directly after the transactions. The Form 4 notes 5,500 ordinary shares are held indirectly by the reporting person’s spouse. The reported sale was effected under a Rule 10b5-1 trading plan adopted on September 14, 2024.
Centessa Pharmaceuticals plc (CNTA) filing a Form 144 notifies a proposed sale of 6,000 common shares to be offered through UBS Financial Services on Nasdaq with an aggregate market value of $103,380.00. The filer reports those shares were acquired the same day, 08/15/2025, by exercising stock options and paid in cash.
The filing also discloses prior sales by the same person, Iqbal Hussain: 12,000 shares sold on 06/24/2025 for $168,218.40 and 6,000 shares sold on 07/15/2025 for $89,566.80. The notice affirms no undisclosed material nonpublic information applies to the seller.
Adage Capital Management, together with principals Robert Atchinson and Phillip Gross, reports beneficial ownership of 8,403,000 ordinary shares of Centessa Pharmaceuticals, representing 6.29% of the outstanding class based on 133,618,774 shares. The shares are ordinary shares underlying ADSs traded under ticker CNTA. The filing shows no sole voting or dispositive power — all voting and dispositive rights are reported as shared — and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing control. The statement contains ownership details and reporting person roles but does not disclose any transaction terms or plans.
Centessa Pharmaceuticals plc (CNTA) reported interim results through June 30, 2025 showing continued clinical progress and a material licensing transaction. For the six months ended June 30, 2025 the company recorded a net loss of $76.5 million versus $81.9 million in the prior year period, with research and development expense of $76.2 million driven primarily by the OX2R agonist programs. Centessa recognized a $15.0 million upfront payment from a LockBody license to Genmab and constrained additional milestone consideration pending achievement. As of June 30, 2025 the company held $404.1 million of cash, cash equivalents and investments and expects those resources to fund operations into mid-2027. The balance sheet shows $109.5 million of long-term debt and an accumulated deficit of $1.07 billion. Operational updates include ORX750 in an ongoing Phase 2a study, IND clearance and Phase 1 initiation for ORX142, and the prior-phase discontinuation of SerpinPC with related termination charges largely paid down.
Centessa Pharmaceuticals plc furnished an earnings update by filing a current report. On August 12, 2025, the company announced its financial results for the quarter ended June 30, 2025 and provided the details in a press release attached as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which limits how it is treated under U.S. securities laws.